These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 342968)

  • 1. Coupling PPD to tumour cells enhances their antigenicity in BCG-primed mice.
    Lachmann PJ; Sikora K
    Nature; 1978 Feb; 271(5644):463-4. PubMed ID: 342968
    [No Abstract]   [Full Text] [Related]  

  • 2. The heterogenization of tumour cells with tuberculin. II. Studies of the antigenicity of tuberculin-heterogenized murine tumour cells in syngeneic BCG positive and BCG negative mice.
    Vyakarnam A; Lachmann PJ; Sikora K
    Immunology; 1981 Feb; 42(2):337-48. PubMed ID: 6161889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunopotentiation with BCG. IV. Factors affecting the magnitude of an antitumor response.
    Hawrylko E; Mackaness GB
    J Natl Cancer Inst; 1973 Nov; 51(5):1683-8. PubMed ID: 4587143
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunopotentiation with BCG. 3. Modulation of the response to a tumor-specific antigen.
    Hawrylko E; Mackaness GB
    J Natl Cancer Inst; 1973 Nov; 51(5):1677-82. PubMed ID: 4587142
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunological adjuvants in cancer immunotherapy.
    Baldwin RW
    Dev Biol Stand; 1977 Apr 13-15; 38():3-12. PubMed ID: 344097
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of cell-wall skeleton of Mycobacterium bovis BCG on cell-mediated cytotoxicity in tumor-bearing mice.
    Taniyama T; Azuma I; Aladin AA; Yamamura Y
    Gan; 1975 Dec; 66(6):705-9. PubMed ID: 817955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of a tuberculin purified protein derivative--Asn-Ala-Asn-Pro conjugate in bacillus Calmette-Guérin primed mice overcomes H-2 restriction of the antibody response and avoids the need for adjuvants.
    Lussow AR; Del Giudice G; Rénia L; Mazier D; Verhave JP; Verdini AS; Pessi A; Louis JA; Lambert PH
    Proc Natl Acad Sci U S A; 1990 Apr; 87(8):2960-4. PubMed ID: 2183219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raising antibodies by coupling peptides to PPD and immunizing BCG-sensitized animals.
    Lachmann PJ; Strangeways L; Vyakarnam A; Evan G
    Ciba Found Symp; 1986; 119():25-57. PubMed ID: 3015516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCG in cancer immunotherapy: results obtained with various BCG preparations in a screening study for systemic adjuvants applicable to cancer immunoprophylaxis or immunotherapy.
    Mathé G; Halle-Pannenko O; Bourut C
    Natl Cancer Inst Monogr; 1973 Dec; 39():107-13. PubMed ID: 4150738
    [No Abstract]   [Full Text] [Related]  

  • 10. Vertical transmission of tumour resistance in guinea pigs.
    Wainberg MA; Minden P; Weiss DW
    Nature; 1976 Jan; 259(5540):213-5. PubMed ID: 175279
    [No Abstract]   [Full Text] [Related]  

  • 11. Activated macrophages and the antitumor action of BCG.
    Alexander P
    Natl Cancer Inst Monogr; 1973 Dec; 39():127-33. PubMed ID: 4595313
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunotherapeutic and immunoprophylactic effects of BCG on 3-methylcholanthrene-induced autochthonous tumors in Swiss mice.
    Tokunaga T; Yamamoto S; Nakamura RM; Kataoka T
    J Natl Cancer Inst; 1974 Aug; 53(2):459-63. PubMed ID: 4602061
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunotherapy of guinea pig cancer with BCG.
    Zbar B
    Johns Hopkins Med J Suppl; 1974; 3():121-30. PubMed ID: 4608693
    [No Abstract]   [Full Text] [Related]  

  • 14. Augmentation of anti-tumor activity by immunization with Mycobacterium tuberculosis (Tbc) and tuberculin-coupled tumor cells.
    Yada Y; Tanaka N; Orita K
    Acta Med Okayama; 1985 Apr; 39(2):131-41. PubMed ID: 3923781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of immunity against murine syngeneic tumors by a fraction extracted from non-pathogenic mycobacteria.
    Lamensans A; Chedid L; Lederer E; Rosselet JP; Gustafson RH; Spencer HJ; Ludwig B; Berger FM
    Proc Natl Acad Sci U S A; 1975 Sep; 72(9):3656-60. PubMed ID: 171670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of transplantation resistance to murine L1210 leukemia cells in BCG-primed mice by immunization with tuberculin protein-coupled L1210 cells.
    Ohno R; Kodera Y; Ogura M; Yamada H
    Gan; 1984 Feb; 75(2):187-92. PubMed ID: 6428959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour models for screening immunomodulators: suppression of tumour growth by delayed hypersensitivity reactions.
    Pimm MV; Baldwin RW
    Behring Inst Mitt; 1984 May; (74):214-8. PubMed ID: 6383324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiation therapy and immunotherapy: the value of immunotherapy in the control of local and regional cancer.
    Cancer; 1976 Apr; 37(4 Suppl):2108-19. PubMed ID: 769945
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of the combination of tumor-specific and nonspecific immunization on tumor suppression.
    Mori T; Sekiguchi M; Fujii G; Inou T; Kitamura M
    J Surg Oncol; 1977; 9(4):359-70. PubMed ID: 408563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of humoral immune responses. I. Potentiating influence of purified protein derivative on the invitro immune response of spleen cells sensitized to Mycobacterium bovis and Mycobacterium avium.
    Muscoplat CC; Setcavage TM; Thoen CO; Kim YB
    Int Arch Allergy Appl Immunol; 1976; 52(1-4):266-72. PubMed ID: 797671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.